CA153、CA125联合HER－2检测在乳腺癌各临床分期诊断中的应用

目的：探讨血清肿瘤标志物CA153、CA125与HER－2联合检测在不同病理分期乳腺癌诊断中的作用。方法：检测2015年1月－2016年1月在我院住院治疗、均有明确病理诊断的乳腺癌患者168例（按临床分期标准分Ⅰ－Ⅱ期86例、Ⅲ期50例、Ⅳ期32例），92例乳腺良性疾病患者和66例健康女性间血清CA153、CA125和HER－2。分析其在不同临床分期乳腺癌诊断中的作用。结果：各临床分期乳腺癌患者的血清CA153、CA125和HER－2水平随着分期的增加而增高，均高于乳腺良性疾病组和健康对照组，差异有统计学意义（P＜0．05）。结论：血清CA153、CA125及HER－2虽属于不同的血清肿瘤标志物，但与乳腺癌均具有相关性，在乳腺癌不同分期诊断中有一定的价值。三者联合检测诊断效果更加明显。

The role of CA153,CA125,HER-2 combined detection for the diagnosis of breast cancer

Objective:To investigate the role of serum tumor markers CA153,CA125,HER-2 combined detection for the diagnosis of breast cancer.Methods:To detect the level of serum CA153,CA125 and HER-2 in 168 cases breast cancer patients confirmed by histology (stage I-II 86 cases,stage III 50 cases,stage IV 32 cases),92 cases of benign breast disease and 66 cases of healthy women.Results:The serum levels of CA153,CA125 and HER-2 in patients with breast cancer were higher than those in benign disease group and healthy control group,and the differ-ence was statistically significant (P<0.05).Conclusion:Serum CA153,CA125 and HER-2 are different kinds of serum tumor markers but associated with breast cancer,in different breast cancer staging diagnosis have certain value. Combined detection of the three markers was more effective.